Skip to main content
SpringerLink
Log in

Diagnostic Efficiency of Determining CXCR1, CXCR2 and Hyaluronic Acid in Blood of Patients with Non-Small Cell Lung Cancer

  • Published:
Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry Aims and scope Submit manuscript

Abstract—

Non-small cell lung cancer (NSCLC) accounts for most cases of lung cancer. Histologically, it is subdivided into two histological subtypes: adenocarcinoma (AC) and squamous cell carcinoma (SCC). The five-year survival rate of patients with stage I NSCLC is two times higher than in patients with stage II and more than five times higher than in stage III−IV lung cancer patients. Currently, there are no informative blood biomarkers to diagnose early stages of NSCLC. The aim of this study was to evaluate complex determination of hyaluronic acid (HA), lymphocyte CXCR2 and granulocyte CXCR1 levels in the blood of patients with AC and SCC. Blood samples from 107 patients with SCC, 90 patients with AC, and 40 healthy people were used in this study. Concentration of HA in blood serum was determined by enzyme linked immunoassay. The level of CXCR2 and CXCR1 was determined by flow cytometry. Diagnostic parameters were determined by constructing mathematical models in the form of regression equations using the method of stepwise inclusion of predictors and subsequent ROC-analysis. Results of the study indicate that MFI CXCR1 in granulocytes, the proportion of lymphocytes expressing CXCR2 and concentration of HA in blood serum in stage I AC and SCC are significantly higher than in healthy people. The level of these indicators significantly increases at stage II of the disease compared to stage I and demonstrates further growth at its later stages. Based on obtained results, regression equations were created. These included: (i) MFI CXCR1 in granulocytes, the proportion of lymphocytes supplied with CXCR2 and the HA serum concentration in to detect stages I−II SCC (diagnostic sensitivity 95.7%, specificity 93.7%, threshold value 0.59) and stages III−IV SCC (diagnostic sensitivity 93.1%, specificity 93.3%, threshold value 0.64); (ii) the proportion of lymphocytes supplied with CXCR2, MFI CXCR1 in granulocytes and CYFRA 21-1 blood level, for detection of I−II stages of AC (sensitivity 91.3%, specificity 94.7%, threshold value 0.61); (iii) the proportion of lymphocytes expressing CXCR2 and CYFRA 21-1 blood level, for detection of AC stages III–IV (sensitivity 94.6%, specificity 91.3%, threshold value 0.15); (IV) the proportion of lymphocytes expressing CXCR2 and serum HA level to differentiate stage II SCC from stage I (sensitivity 94.4%, specificity 87.5%, threshold value 0.44) and II stage AC from stage I (sensitivity 88.5%, specificity 91.2%, threshold value 0.46).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.

Similar content being viewed by others

REFERENCES

  1. Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., and Soerjomataram, I., CA Cancer J. Clin., 2020, vol. 71, no. 3, pp. 209–249. https://doi.org/10.3322/caac.21660

    Article  Google Scholar 

  2. Raso, M.G. and Wistuba, I.I., J. Thoracic Oncol., 2007, vol. 2, no. 7, pp. 128–135. https://doi.org/10.1097/JTO.0b013e318074fe42

    Article  Google Scholar 

  3. Rosen, R.D. and Sapra, A., TNM Classification, StatPearls Publishing, NCBI Bookshelf, 2021.

  4. Wang, B.Y., Huang, J.Y., Chen, H.C., Lin, C.H., Lin, S.H., Hung, W.H., and Cheng, Y.F., J Cancer Res. Clin. Oncol., 2020, vol. 146, no. 1, pp. 43–52. https://doi.org/10.1007/s00432-019-03079-8

    Article  PubMed  Google Scholar 

  5. Kulpa, J., Wójcik, E., Reinfuss, M., and Kołodziejski, L., Clin. Chem., 2002, vol. 48, no. 11, pp. 1931–1937.

    Article  CAS  Google Scholar 

  6. Liu, Q., Li, A., Tian, Y., Wu, J.D., Liu, Y., Li, T., Chen, Y., Han, X., and Wu, K., Cytokine Growth Factor Rev., 2016, vol. 31, pp. 61–71. https://doi.org/10.1016/j.cytogfr.2016.08.002

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wang, L., Shi, L., Gu, J., Zhan, C., Xi, J., Ding, J., and Ge, D., J. Physiol. Biochem., 2018, vol. 74, no. 2, pp. 313–324. https://doi.org/10.1007/s13105-018-0619-z

    Article  CAS  PubMed  Google Scholar 

  8. Pirinen, R., Tammi, R., Tammi, M., Hirvikoski, P., Parkkinen, J.J., Johansson, R., Böhm, J., Hollmén, S., and Kosma, V.M., Int. J. Cancer, 2001, vol. 95, no. 1, pp. 12–17. https://doi.org/10.1002/1097-0215(20010120)95:1<12:: aid-ijc1002>3.0.co;2-e

  9. Bamji-Stocke, S., van Berkel, V., and Frieboes, B.H., Metabolomics, 2018, vol. 14, no. 6, 81. https://doi.org/10.1007/s11306-018-1376-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zhenyu, S., Chen, X., and Wang, X., Biomarker Res., 2016, vol. 4, 11. https://doi.org/10.1186/s40364-016-0065-4

    Article  Google Scholar 

  11. Liu, Y., Wu, B., Geng, H., Xu, M., and Zhong, H., Oncol. Lett., 2015, vol. 10, no. 3, pp. 1315–1322. https://doi.org/10.3892/ol.2015.3402

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Rangel, M.P., de Sá, V.K., Martins, V., Mar-tins, J.R.M., Parra, E.R., Mendes, A., Andrade, P.S., Reis, R.M., Longatto-Filho, A., Oliveira, C.Z., Takagaki, T., Carraro, D.M., Nader, H.B., and Capelozzi, V.L., Braz. J. Med. Biol. Res., 2015, vol. 48, no. 6, pp. 557–567. https://doi.org/10.1590/1414-431X20144300

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lin, W., Yugang, L., Yuefeng, M., Chao, D., Huijun, Z., Zhenghui, L., Zhenning, G., and Changsheng, Z., Cell Cycle, 2019, vol. 18, no. 24, pp. 3456–3471. https://doi.org/10.1080/15384101.2019.1689471

    Article  CAS  Google Scholar 

  14. Rajul, P., Mathai, A., Shefali, S., Chandra, S., and Ravi, T., Indian J. Ophtalmol., 2008, vol. 56, no. 1, pp. 45–50. https://doi.org/10.4103./0301-4738.37595

    Article  Google Scholar 

  15. Fang, R., Zhu, Y., Khadka1,V.S., Zhang, F., Jiang, B., and Deng, Y., Front. Physiol., 2018, vol. 9, 1710. https://doi.org/10.3389/fphys.2018.01710

    Article  PubMed  PubMed Central  Google Scholar 

  16. Li, X., Asmitananda, T., Gao, L., Gai, D., Song, Z., Zhang, Y., Ren, H., Yang, T., Chen, T., and Chen, M., Neoplasma, 2012, vol. 59, no. 5, pp. 500–507.

    Article  CAS  Google Scholar 

  17. Hernandez-Hernandez, J.R., Garcia-Garcia, J.M., and Martinez, M.T., Int. J. Biol. Markers, 1995, vol. 10, no. 3, pp. 149–155. https://doi.org/10.1177/172460089501000304

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was financially supported by the budget of the Republic of Belarus.

Author information

Authors and Affiliations

  1. Belarusian State Medical University, ul. Dzerzhinskogo 83, 220116, Minsk, Belarus

    D. I. Murashka, A. D. Tahanovich & M. M. Kauhanka

  2. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology (RSPC), 223040, Lesnoy, Minsk oblast, Belarus

    V. I. Prokhorova & O. V. Gotko

Authors
  1. D. I. Murashka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. D. Tahanovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. M. Kauhanka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. I. Prokhorova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. V. Gotko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. I. Murashka.

Ethics declarations

The authors declare that they have no conflict of interest.

Studies using biological body fluids of patients were carried out on the basis of the “Rules and norms of humane treatment of biological research objects” and were approved at a meeting of the Committee on Biomedical Ethics (protocol no. 2 dated October 4, 2021) of the Belarusian State Medical University. All study participants gave informed consent to participate in the study and use their biological samples in it.

Additional information

Translated by A. Medvedev

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Murashka, D.I., Tahanovich, A.D., Kauhanka, M.M. et al. Diagnostic Efficiency of Determining CXCR1, CXCR2 and Hyaluronic Acid in Blood of Patients with Non-Small Cell Lung Cancer. Biochem. Moscow Suppl. Ser. B 16, 45–53 (2022). https://doi.org/10.1134/S1990750822010073

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S1990750822010073

Keywords:

Search

Navigation